MarketMoodz
Lilly's retatrutide clears first late-stage diabetes trial
CNBC's summary of the trial readout shows Eli Lilly's retatrutide clearing its first late-stage trial in Type 2 diabetes, hitting the primary efficacy endpoint. HbA1c fell about 1.7% to 2% at 40 weeks across doses, with strong weight loss at the highest dose. The CNBC report has not been independently verified, and Lilly has not filed for approval yet, with seven more Phase 3 readouts expected this year.
Key Takeaways
- Retatrutide met its primary endpoint in a Phase 3 Type 2 diabetes trial, per CNBC readout.
- HbA1c reductions averaged 1.7%–2% at 40 weeks across doses versus placebo.
- Weight loss at the highest dose averaged 16.8% (36.6 pounds) at 40 weeks among adherent patients; 15.3% when including all participants.
- Discontinuations due to adverse events were around 5%.
- Lilly positions retatrutide as a next pillar after Zepbound, with seven more Phase 3 results planned by year-end; no head-to-head trials exist yet.
People Involved
- Ken Custer President of Lilly Cardiometabolic Health
Entities Involved
- Eli Lilly and Company Developer of retatrutide and obesity/diabetes drugs
- Zepbound (tirzepatide) Lilly obesity/diabetes drug; benchmark for weight loss and glycemic control
- Orforglipron Lilly oral obesity/diabetes candidate
- Novo Nordisk Rival pursuing multi-hormone obesity/diabetes programs
MarketMoodz Analysis
For investors, the readout strengthens Lilly's growth narrative in the obesity/diabetes space by suggesting that the triple-hormone approach can deliver solid glycemic control and competitive weight loss in a Type 2 diabetes population. Even though the drug has not filed for approval yet, the data could accelerate regulatory discussions and set expectations for pricing, payer coverage, and market access once filings begin.
Historically, Lilly’s Zepbound has delivered meaningful weight loss but with more modest gains in some trials, while SURPASS-1 and SURPASS-2 showed weight losses up to about 11%–13% and A1c reductions that sometimes exceeded 2%. Cross-trial comparisons are imperfect, but retatrutide’s 1.7%–2% HbA1c drop and higher weight-loss potential underscore the competitive thrust of triple-hormone strategies relative to single- or two-hormone therapies.
Looking ahead, seven additional Phase 3 readouts are planned by year-end, potentially informing regulatory timelines and filings. Watch for regulatory submissions, pricing/payer dynamics, and how Novo Nordisk’s rival programs evolve as both companies push multi-hormone approaches toward market authorization.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial